Altium Capital Management’s NLS Pharmaceutics Warrant NLSPW Stock Holding History

Altium Capital Management’s Portfolio NLSPW Stock Details NLSPW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-200,000	Closed	-$2.28K	–	83
2024 Q3	$2.28K	Hold	200,000	–	–	﹤0.01%	74
2024 Q2	$6.9K	Hold	200,000	–	–	﹤0.01%	58
2024 Q1	$6.88K	Hold	200,000	–	–	﹤0.01%	58
2023 Q4	$11.2K	Hold	200,000	–	–	0.01%	48
2023 Q3	$21K	Hold	200,000	–	–	0.01%	54
2023 Q2	$21.4K	Hold	200,000	–	–	0.02%	49
2023 Q1	$30K	Hold	200,000	–	–	0.02%	71
2022 Q4	$38K	Hold	200,000	–	–	0.02%	74
2022 Q3	$43K	Hold	200,000	–	–	0.02%	116
2022 Q2	$24K	Hold	200,000	–	–	0.01%	114
2022 Q1	$76K	Hold	200,000	–	–	0.03%	106
2021 Q4	$146K	Buy	+200,000	New	+$129K	0.04%	119

Other funds holding NLSPW

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Altium Capital Management's NLSPW Position: Q4 2024 in Review

Altium Capital Management sold out of NLS Pharmaceutics Warrant (NLSPW) in Q4 2024, closing a stake of 200,000 shares — an estimated $2.28K sold.

Altium Capital Management first reported a position in NLSPW in Q4 2021 and held it in 12 quarters. The position peaked at $146K in Q4 2021. 5 funds tracked by Wall St. Rank hold NLSPW as of Q4 2024.

Altium Capital Management reported no remaining NLS Pharmaceutics Warrant position as of Q4 2024 after selling out during the quarter.
Altium Capital Management sold 200,000 NLS Pharmaceutics Warrant shares in Q4 2024, an estimated $2.28K.
Altium Capital Management first reported a position in NLS Pharmaceutics Warrant in Q4 2021 and held it in 12 quarters.
Altium Capital Management's NLS Pharmaceutics Warrant position peaked at $146K in Q4 2021.
5 funds tracked by Wall St. Rank held NLS Pharmaceutics Warrant as of Q4 2024.

Based on Altium Capital Management's 13F filing for Q4 2024, filed 13 Feb 2025.